NeoGenomics Cash Flow Statement
NASDAQ: NEOHealth CarePrecision InstrumentsUSD
16.35+0.33 (+2.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NeoGenomics free cash flow
In fiscal 2025, NeoGenomics generated $5.2 million of operating cash flow and spent $27.0 million on capital expenditures. That left free cash flow of -$21.8 million, a free-cash-flow margin of -3.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
NeoGenomics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -108.03M | -78.73M | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -396.00K | -6.14M |
| Net Income growth (YoY) | — | — | — | — | -300.07% | -47.89% | +203.26% | — | — | — |
| Depreciation & Amortization | 36.07M | 39.10M | 37.45M | 35.37M | 30.19M | 25.90M | 20.35M | 15.80M | 15.60M | 15.94M |
| Stock-Based Compensation | 41.32M | 33.41M | 24.63M | 24.67M | 22.46M | 10.21M | 10.00M | 6.96M | 6.44M | 5.44M |
| Change in Working Capital | -21.83M | -19.56M | -2.13M | -8.00M | 6.65M | -27.80M | -23.05M | 943.00K | -7.02M | -7.71M |
| Operating Cash Flow | 5.23M | 7.02M | -1.95M | -65.99M | -26.72M | 1.46M | 23.37M | 44.79M | 18.04M | 21.48M |
| Capital Expenditures | -27.01M | -41.06M | -28.75M | -30.89M | -64.14M | -29.10M | -20.03M | -14.31M | -13.69M | -7.54M |
| Investing Cash Flow | -12.34M | 12.86M | 76.71M | 517.00K | -632.37M | -159.44M | -19.63M | -139.69M | -13.69M | -6.50M |
| Debt Repaid | — | — | — | — | — | — | — | -6.56M | -5.42M | -5.29M |
| Financing Cash Flow | -200.29M | 4.65M | 4.55M | 11.83M | 725.28M | 235.60M | 159.47M | 91.96M | -4.09M | -25.87M |
| Net Change in Cash | -207.39M | 24.52M | 79.31M | -53.65M | 66.19M | 77.62M | 163.21M | -3.01M | 296.00K | -10.89M |
| Free Cash Flow | -21.78M | -34.04M | -30.70M | -96.88M | -90.86M | -27.64M | 3.34M | 30.48M | 4.35M | 13.94M |
This table shows 10 annual periods of NeoGenomics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NEO's reporting calendar. What is a cash flow statement?